Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation

Posted on by

-Data demonstrates durable responses across 3 cohorts of patients with recurrent and newly diagnosed GBM- -Data supports continued clinical development of ST101 as a backbone treatment in combination with standard-of-care and immune-oncology agents- TARRYTOWN, N.Y., June 1, 2024…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.